Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial

Camilla K Lonkvist, Simon Lønbro, Anders Vinther, Bo Zerahn, Eva Rosenbom, Hanne Primdahl, Pernille Hojman, Julie Gehl, Camilla K Lonkvist, Simon Lønbro, Anders Vinther, Bo Zerahn, Eva Rosenbom, Hanne Primdahl, Pernille Hojman, Julie Gehl

Abstract

Background: Head and neck cancer patients undergoing concomitant chemoradiotherapy (CCRT) frequently experience loss of muscle mass and reduced functional performance. Positive effects of exercise training are reported for many cancer types but biological mechanisms need further elucidation. This randomized study investigates whether progressive resistance training (PRT) may attenuate loss of muscle mass and functional performance. Furthermore, biochemical markers and muscle biopsies will be investigated trying to link biological mechanisms to training effects.

Methods: At the Departments of Oncology at Herlev and Aarhus University Hospitals, patients with stage III/IV squamous cell carcinoma of the head and neck, scheduled for CCRT are randomized 1:1 to either a 12-week PRT program or control group, both with 1 year follow-up. Planned enrollment is 72 patients, and stratification variables are study site, sex, p16-status, and body mass index. Primary endpoint is difference in change in lean body mass (LBM) after 12 weeks of PRT, assessed by dual-energy X-ray absorptiometry (DXA). The hypothesis is that 12 weeks of PRT can attenuate the loss of LBM by at least 25%. Secondary endpoints include training adherence, changes in body composition, muscle strength, functional performance, weight, adverse events, dietary intake, self-reported physical activity, quality of life, labor market affiliation, blood biochemistry, plasma cytokine concentrations, NK-cell frequency in blood, sarcomeric protein content in muscles, as well as muscle fiber type and fiber size in muscle biopsies. Muscle biopsies are optional.

Discussion: This randomized study investigates the impact of a 12-week progressive resistance training program on lean body mass and several other physiological endpoints, as well as impact on adverse events and quality of life. Furthermore, a translational approach is integrated with extensive biological sampling and exploration into cytokines and mechanisms involved. The current paper discusses decisions and methods behind exercise in head and neck cancer patients undergoing concomitant chemoradiotherapy.

Trial registration: Approved by the Regional Ethics Committee for the Capital Region of Denmark (protocol id: H-15003725) and registered retrospectively at ClinicalTrials.gov ( NCT02557529 ) September 11th 2015.

Keywords: Body composition; Body weight; Chemoradiotherapy; Exercise; Head and neck cancer; Head and neck squamous cell carcinoma; Lean body mass; Physical activity; Progressive resistance training; Weight.

Figures

Fig. 1
Fig. 1
Overall study design

References

    1. Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. Head Neck. 2014;36(9):1356–1362.
    1. Langius JE, Van Dijk AM, Doornaert P, Kruizenga HM, Langendijk JA, Leemans CR, et al. More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer. 2013;65(1):76–83. doi: 10.1080/01635581.2013.741749.
    1. Lonbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Overgaard J, et al. Lean body mass and muscle function in head and neck cancer patients and healthy individuals--results from the DAHANCA 25 study. Acta Oncol. 2013;52(7):1543–1551. doi: 10.3109/0284186X.2013.822553.
    1. Platek ME, Myrick E, Mccloskey SA, Gupta V, Reid ME, Wilding GE, et al. Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways. Support Care Cancer. 2013;21(10):2825–2833. doi: 10.1007/s00520-013-1861-0.
    1. Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck. 2008;30(4):503–508. doi: 10.1002/hed.20737.
    1. Wang C, Vainshtein JM, Veksler M, Rabban PE, Sullivan JA, Wang SC, et al. Investigating the clinical significance of body composition changes in patients undergoing chemoradiation for oropharyngeal cancer using analytic morphomics. Spring. 2016;5:429. doi: 10.1186/s40064-016-2076-x.
    1. Grossberg AJ, Chamchod S, Fuller CD, Mohamed AS, Heukelom J, Eichelberger H, et al. Association of Body Composition with Survival and Locoregional Control of radiotherapy-treated head and neck Squamous cell carcinoma. JAMA Oncol. 2016;2(6):782–789. doi: 10.1001/jamaoncol.2015.6339.
    1. Al-Majid S, Waters H. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs. 2008;10(1):7–20. doi: 10.1177/1099800408317345.
    1. Der-Torossian H, Couch ME, Dittus K, Toth MJ. Skeletal muscle adaptations to cancer and its treatment: their fundamental basis and contribution to functional disability. Crit rev Eukaryot Gene Expr. 2013;23(4):283–297. doi: 10.1615/CritRevEukaryotGeneExpr.2013007650.
    1. Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6(2):132–143. doi: 10.1002/jcsm.12023.
    1. Sakai H, Sagara A, Arakawa K, Sugiyama R, Hirosaki A, Takase K, et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicol Appl Pharmacol. 2014;278(2):190–199. doi: 10.1016/j.taap.2014.05.001.
    1. Lofberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Investig. 2002;32(5):345–353. doi: 10.1046/j.1365-2362.2002.00993.x.
    1. Schakman O, Kalista S, Barbe C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–2172. doi: 10.1016/j.biocel.2013.05.036.
    1. Jager-Wittenaar H, Dijkstra PU, Vissink A, Langendijk JA, Der Laan BFaM V, Pruim J, et al. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Head Neck. 2011;33(6):863–870. doi: 10.1002/hed.21546.
    1. Van Den Berg MG, Rasmussen-Conrad EL, Gwasara GM, Krabbe PF, Naber AH, Merkx MA. A prospective study on weight loss and energy intake in patients with head and neck cancer, during diagnosis, treatment and revalidation. Clin Nutr. 2006;25(5):765–772. doi: 10.1016/j.clnu.2005.12.007.
    1. Deutz NE, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert group. Clin Nutr. 2014;33(6):929–936. doi: 10.1016/j.clnu.2014.04.007.
    1. Hojman P, Fjelbye J, Zerahn B, Christensen JF, Dethlefsen C, Lonkvist CK, et al. Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. PLoS One. 2014;9(9) doi: 10.1371/journal.pone.0109030.
    1. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review. Crit rev Oncol Hematol. 2013;88(3):573–593. doi: 10.1016/j.critrevonc.2013.07.001.
    1. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33(6):548–555. doi: 10.1093/ageing/afh201.
    1. Lonbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Aagaard P, et al. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy--results from the randomized DAHANCA 25B trial. Radiother Oncol. 2013;108(2):314–319. doi: 10.1016/j.radonc.2013.07.002.
    1. Lonbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients--the DAHANCA 25A study. Acta Oncol. 2013;52(2):310–318. doi: 10.3109/0284186X.2012.741325.
    1. Murphy EA, Davis JM, Barrilleaux TL, Mcclellan JL, Steiner JL, Carmichael MD, et al. Benefits of exercise training on breast cancer progression and inflammation in C3(1)SV40Tag mice. Cytokine. 2011;55(2):274–279. doi: 10.1016/j.cyto.2011.04.007.
    1. Abdalla DR, Aleixo AA, Murta EF, Michelin MA. Innate immune response adaptation in mice subjected to administration of DMBA and physical activity. Oncol Lett. 2014;7(3):886–890.
    1. Esser KA, Harpole CE, Prins GS, Diamond AM. Physical activity reduces prostate carcinogenesis in a transgenic model. Prostate. 2009;69(13):1372–1377. doi: 10.1002/pros.20987.
    1. Aoi W, Naito Y, Takagi T, Tanimura Y, Takanami Y, Kawai Y, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013;62(6):882–889. doi: 10.1136/gutjnl-2011-300776.
    1. Rundqvist H, Augsten M, Stromberg A, Rullman E, Mijwel S, Kharaziha P, et al. Effect of acute exercise on prostate cancer cell growth. PLoS One. 2013;8(7) doi: 10.1371/journal.pone.0067579.
    1. Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23(3):554–562. doi: 10.1016/j.cmet.2016.01.011.
    1. Pedersen L, Christensen JF, Hojman P. Effects of exercise on tumor physiology and metabolism. Cancer J. 2015;21(2):111–116. doi: 10.1097/PPO.0000000000000096.
    1. Idorn M, Hojman P. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol med. 2016;22(7):565–577. doi: 10.1016/j.molmed.2016.05.007.
    1. Jones LW. Precision oncology framework for investigation of exercise as treatment for cancer. J Clin Oncol. 2015;33(35):4134–4137. doi: 10.1200/JCO.2015.62.7687.
    1. Sobin LHG, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, Seventh edition edn. Chichester: Wiley-Blackwell; 2009.
    1. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol. 1998;46(2):135–146. doi: 10.1016/S0167-8140(97)00220-X.
    1. American College of Sports Medicine position stand Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2009;41(3):687–708. doi: 10.1249/MSS.0b013e3181915670.
    1. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339:b3410. doi: 10.1136/bmj.b3410.
    1. Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, Mcguigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–2052. doi: 10.1249/01.mss.0000233803.48691.8b.
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 .
    1. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP) Arthritis Care res (Hoboken) 2011;63(Suppl 11):S240–S252. doi: 10.1002/acr.20543.
    1. Andersen LG, Groenvold M, Jorgensen T, Aadahl M. Construct validity of a revised physical activity scale and testing by cognitive interviewing. Scand J Public Health. 2010;38(7):707–714. doi: 10.1177/1403494810380099.
    1. Frankenfield D, Roth-Yousey L, Compher C. Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review. J am Diet Assoc. 2005;105(5):775–789. doi: 10.1016/j.jada.2005.02.005.
    1. Ferrari P, Friedenreich C, Matthews CE. The role of measurement error in estimating levels of physical activity. Am J Epidemiol. 2007;166(7):832–840. doi: 10.1093/aje/kwm148.
    1. Jensen K, Jensen AB, Grau C. A cross sectional quality of life study of 116 recurrence free head and neck cancer patients. The first use of EORTC H&N35 in Danish. Acta Oncol. 2006;45(1):28–37. doi: 10.1080/02841860500417536.
    1. Fong DYT, Ho JWC, Hui BPH, Lee AM, Macfarlane DJ, Leung SSK, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. Bmj. 2012;344:e70. doi: 10.1136/bmj.e70.
    1. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):87–100. doi: 10.1007/s11764-009-0110-5.
    1. Bouillet T, Bigard X, Brami C, Chouahnia K, Copel L, Dauchy S, et al. Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and cancer CAMI. Crit Rev Oncol Hematol. 2015;94(1):74–86. doi: 10.1016/j.critrevonc.2014.12.012.
    1. Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Compr Physiol. 2012;2(4):2775–2809.
    1. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011;28(3):753–765. doi: 10.1007/s12032-010-9536-x.
    1. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer. 2013;133(8):1905–1913. doi: 10.1002/ijc.28208.
    1. Ottosson S, Zackrisson B, Kjellén E, Nilsson P, Laurell G. Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy. Acta Oncol. 2013;52(4):711–718. doi: 10.3109/0284186X.2012.731524.
    1. Brodie DA, Stewart AD. Body composition measurement: a hierarchy of methods. J Pediatr Endocrinol Metab. 1999;12(6):801–816. doi: 10.1515/JPEM.1999.12.6.801.
    1. Jebb SA, Elia M. Techniques for the measurement of body composition: a practical guide. Int J Obes Relat Metab Disord. 1993;17(11):611–621.
    1. Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care. 2008;11(5):566–572. doi: 10.1097/MCO.0b013e32830b5f23.
    1. Visser M, Fuerst T, Lang T, Salamone L, Harris TB. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, aging, and body composition study--dual-energy X-ray Absorptiometry and body composition working group. J Appl Physiol (1985) 1999, 87(4):1513-1520.
    1. Gonzalez Ferreira JA, Jaen Olasolo J, Azinovic I, Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother. 2015;20(5):328–339. doi: 10.1016/j.rpor.2015.05.010.
    1. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42(5):1069–1075. doi: 10.1016/S0360-3016(98)00348-4.
    1. Fortin A, Wang CS, Vigneault E. Effect of pretreatment anemia on treatment outcome of concurrent radiochemotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):255–260. doi: 10.1016/j.ijrobp.2008.04.079.
    1. Overgaard J, Hansen HS, Jorgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 1986;12(4):515–521. doi: 10.1016/0360-3016(86)90058-1.
    1. Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Pedersen BK. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab. 2011;301(3):E504–EE10. doi: 10.1152/ajpendo.00520.2010.
    1. Pedersen BK. Muscles and their myokines. J exp Biol. 2011;214(Pt 2):337–346. doi: 10.1242/jeb.048074.
    1. Gerritsen JK, Vincent AJ. Exercise improves quality of life in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. Br J Sports med. 2016;50(13):796–803. doi: 10.1136/bjsports-2015-094787.
    1. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst rev. 2012;8
    1. Capozzi LC, Mcneely ML, Lau HY, Reimer RA, Giese-Davis J, Fung TS, et al. Patient-reported outcomes, body composition, and nutrition status in patients with head and neck cancer: results from an exploratory randomized controlled exercise trial. Cancer. 2016;122(8):1185–1200. doi: 10.1002/cncr.29863.
    1. Rogers LQ, Anton PM, Fogleman A, Hopkins-Price P, Verhulst S, Rao K, et al. Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer. Head Neck. 2013;35(8):1178–1188. doi: 10.1002/hed.23118.
    1. Samuel SR, Maiya GA, Babu AS, Vidyasagar MS. Effect of exercise training on functional capacity & quality of life in head & neck cancer patients receiving chemoradiotherapy. Indian J med res. 2013;137(3):515–520.
    1. Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, et al. Maintaining physical activity during head and neck cancer treatment: results of a pilot controlled trial. Head Neck. 2016;38(Suppl 1):E1086–E1096. doi: 10.1002/hed.24162.
    1. Deschler DG, Richmon JD, Khariwala SS, Ferris RL, Wang MB. The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014;151(3):375–380. doi: 10.1177/0194599814538605.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться